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Clinical trials of therapeutic angiogenesis by vascular endothelial
growth factor (VEGF) gene delivery failed to show efficacy. Major
challenges include the need to precisely control in vivo distribution
of growth factor dose and duration of expression. Recombinant
VEGF protein delivery could overcome these issues, but rapid in
vivo clearance prevents the stabilization of induced angiogenesis.
Here, we developed an optimized fibrin platform for controlled
delivery of recombinant VEGF, to robustly induce normal, stable,
and functional angiogenesis. Murine VEGF164 was fused to a
sequence derived from α2-plasmin inhibitor (α2-PI1–8) that is a sub-
strate for the coagulation factor fXIIIa, to allow its covalent cross-
linking into fibrin hydrogels and release only by enzymatic
cleavage. An α2-PI1–8–fused variant of the fibrinolysis inhibitor
aprotinin was used to control the hydrogel degradation rate,
which determines both the duration and effective dose of factor
release. An optimized aprotinin-α2-PI1–8 concentration ensured
ideal degradation over 4 wk. Under these conditions, fibrin-
α2-PI1–8-VEGF164 allowed exquisitely dose-dependent angiogenesis:
concentrations ≥25 μg/mL caused widespread aberrant vascular
structures, but a 500-fold concentration range (0.01–5.0 μg/mL)
induced exclusively normal, mature, nonleaky, and perfused
capillaries, which were stable after 3 mo. Optimized delivery of
fibrin-α2-PI1–8-VEGF164 was therapeutically effective both in ische-
mic hind limb and wound-healing models, significantly improving
angiogenesis, tissue perfusion, and healing rate. In conclusion, this
optimized platform ensured (i) controlled and highly tunable
delivery of VEGF protein in ischemic tissue and (ii) stable and
functional angiogenesis without introducing genetic material and
with a limited and controllable duration of treatment. These findings
suggest a strategy to improve safety and efficacy of therapeutic
angiogenesis.
Therapeutic angiogenesis is an attractive strategy for treatingischemic conditions, such as peripheral and coronary ar-
tery diseases or chronic wounds, in which the intrinsic capacity
for spontaneous vascular repair and tissue regeneration is
either compromised or insufficient to restore physiological
blood flow. In fact, sufficient expansion of microvascular net-
works is capable of increasing flow in upstream collateral
arteries through retrograde signals (1, 2), thereby providing
effective bypass of the obstructed feeding vessels. Vascular
endothelial growth factor (VEGF) is the master regulator
of both developmental and reparative vascular growth (3).
However, initial clinical trials of VEGF gene delivery failed
to establish clinical benefit (4). Retrospective analyses iden-
tified several issues that undermined the efficacy of those tri-
als, particularly the difficulty to deliver a sufficient VEGF
dose into the target tissue at safe vector doses (5, 6). By cell-
based gene delivery, we previously found that, to effectively
exploit VEGF’s therapeutic potential and robustly induce only
functional and safe angiogenesis, it is key to control its microen-
vironmental concentration around each producing cell in vivo
rather than its total dose (7) as VEGF binds tightly to the extra-
cellular matrix (ECM) (8). However, it is challenging to achieve
homogeneous expression levels in vivo with gene-therapy vec-
tors. Further, newly induced vessels require sustained VEGF
stimulation for at least 4 wk to stabilize and persist indefinitely,
but unlimited duration of expression raises safety concerns (7, 9,
10). Controlled release of recombinant VEGF protein from bio-
degradable matrices is an attractive approach for clinical trans-
lation of these biological concepts due to the lack of genetic
modification, the ease of achieving a homogenous dose distribu-
tion, and the limited duration of treatment (11).
Physiological angiogenesis crucially depends on a spatially
restricted organization of growth factors through their binding to
the ECM (12). Fibrin, a natural product of blood coagulation,
provides unique features for physiological presentation of angio-
genic signals: (i) It is injectable as a liquid and solidifies in situ
without cytotoxicity; (ii) it is remodeled by cell-associated enzymes
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like metalloproteinases and plasmin; and (iii) it is a natural cell-
infiltration matrix (13). Therefore, we previously developed an
approach to enzymatically link growth factors into fibrin hydrogels:
the α2-plasmin inhibitor-derived octapeptide NQEQVSPL (α2-PI1–8),
which is a substrate for the transglutaminase coagulation factor
fXIIIa and has no plasmin inhibitory function itself, fused onto
a factor N terminus, ensures its covalent binding to fibrin during
the fibrinogen cross-linking reaction and subsequent release only
through matrix degradation by local cell-associated proteases
(14, 15). Matrix-bound presentation of diverse so-engineered growth
factors, such as α2-PI1–8–fused variants of VEGF-A121, BMP-2, and
IGF1, considerably accentuated their biological effects compared
with the wild-type factors (16–19). However, the brief persistence
of fibrin hydrogels in vivo (16) is insufficient to ensure stabili-
zation of newly induced vessels and is a major obstacle to its
exploitation for therapeutic angiogenesis (20). To gain control
over fibrin-remodeling rates and significantly prolong gel per-
sistence in vivo, we have engineered an α2-PI1–8–fused variant
of the fibrinolysis inhibitor aprotinin (21). Here, we developed
a fibrin platform to ensure both controlled and sustained delivery
of α2-PI1–8-VEGF-A164 and achieve robust induction of normal,
stable, and functional angiogenesis in therapeutically relevant
target tissues.
Results
Generation of a Recombinant Murine VEGF164 Variant, α2PI1–8-VEGF164.
The α2-PI1–8 peptide was fused at the N terminus of murine
VEGF164 by a previously developed method of protein engineer-
ing (15). The coupling efficiency of α2-PI1–8-VEGF164 in fibrin gels
was determined measuring the factor release into buffer every 24 h
over 7 d: 5.1 ± 1.2% of the incorporated α2-PI1–8-VEGF164 was
released in the first day without significant increases by 7 d (6.9 ±
1.2%) whereas the native VEGF164 was almost completely re-
leased already after 1 d (88.2 ± 2.4%) (Fig. S1A). The bioactivity
of α2-PI1–8-VEGF164 was equivalent to native VEGF164, as de-
termined by their ability to induce VEGFR-2 phosphorylation on
endothelial cells (Fig. S1B).
In Vivo Fibrin-Gel Degradation as a Function of Composition. Fibrin-
ogen content proportionally determines the maximum amount of
α2-PI1–8-VEGF incorporated into the gel. Therefore, the highest
concentration compatible with in vivo injection in liquid form
(polymerization time >10 s) was determined to be 25 mg/mL and
selected for subsequent experiments. Small-strain oscillatory shear
rheometry showed that gel stiffness varied between 2.9 ± 0.4 and
6.9 ± 1.2 kPa, depending on the concentration of cross-linking
enzymes. To determine the effect of gel composition on in vivo
degradation rate after intramuscular injection, the amount of re-
maining gel was assessed by histological analysis after 4 d (Fig. S2A)
and by noninvasive multispectral imaging of gels labeled with
fluorescent fibrinogen (Fig. S2B). All compositions showed similar
gel persistence and degradation rates, being essentially consumed
by 5 d (Fig. S2). Therefore, the composition with the lowest
stiffness (2.9 kPa: fibrinogen 25 mg/mL, FXIII 2 U/mL, thrombin
2 U/mL) was selected to investigate growth-factor delivery in vivo,
to maximize compliance and minimize tissue invasiveness.
Aprotinin-α2-PI1–8 Concentration Determines both Rate and Duration
of VEGF Release.Aprotinin inhibits fibrin degradation by proteases,
and the engineered variant aprotinin-α2-PI1–8 (21) was covalently
cross-linked in the gels to prolong in vivo persistence and the
duration of VEGF release, required for vascular stabilization.
Gel degradation rate affects both key parameters controlling an-
giogenesis (i.e., the rate and duration of VEGF release), but in
opposite directions, as a reduction in degradation rate would in-
crease the duration of VEGF release but also reduce its rate (i.e.,
the effective delivered dose). Therefore, we first sought to de-
termine the optimal aprotinin-α2-PI1–8 concentration that would
ensure both sufficient in vivo persistence and an adequate VEGF
release rate. Gels were prepared with the maximum α2-PI1–8-
VEGF164 concentration that would not affect their mechanical
properties (100 μg/mL) and a fourfold lower one (25 μg/mL), in
combination with three different aprotinin-α2-PI1–8 concen-
trations (17 μg/mL, 56 μg/mL, and 85 μg/mL), to analyze the
effect of aprotinin-α2-PI1–8 dose on the effective VEGF release
rate, based on induced vascular morphology. As shown in Fig.
1, 9 d after intramuscular injection, the negative control gels,
containing only aprotinin-α2-PI1–8, did not induce any angio-
genesis whereas 100 μg/mL α2-PI1–8-VEGF164 induced aberrant
vessels independently of aprotinin concentration. Such vessels
displayed irregularly dilated diameters and multiple lumens,
were devoid of pericytes, and were covered with a thick layer
of smooth muscle cells, similar to previously described angi-
oma-like structures induced by excessive VEGF doses (7).
However, the effects of the fourfold lower α2-PI1–8-VEGF164
concentration of 25 μg/mL were clearly dependent on apro-
tinin-α2-PI1–8 amount: no angiogenesis was detectable with 85
μg/mL, aberrant angioma-like structures were induced with 17
μg/mL, and an abundant network of morphologically normal,
pericyte-covered capillaries was generated with the interme-
diate 56 μg/mL concentration, even if rare enlarged vessels were
still detectable. Thus, an aprotinin-α2-PI1–8 concentration of 56
μg/mL, which allowed a VEGF dose-dependent transition be-
tween normal and aberrant angiogenesis, was used in subsequent
experiments.
α2-PI1–8-VEGF164 Bioactivity After Gel Incorporation and in Vivo
Implantation. To determine whether α2-PI1–8-VEGF164 could
retain its bioactivity while incorporated into the fibrin gels in
vivo, before being released, gels were preformed at 37 °C with
100 μg/mL α2-PI1–8-VEGF164 and 56 μg/mL aprotinin-α2-PI1–8
and implanted s.c. in nude mice. After 2 wk, gels still contained
Fig. 1. Aprotinin-α2-PI1–8 concentration determines the effective released
dose of α2-PI1–8-VEGF164 and the angiogenic outcome. Fibrin gels were
injected into the gastrocnemius muscles of SCID mice, and tissues were an-
alyzed 9 d later. Two different α2-PI1–8-VEGF164 concentrations (25 μg/mL and
100 μg/mL) were tested in combination with three aprotinin-α2-PI1–8 con-
centrations (17 μg/mL, 56 μg/mL, and 81 μg/mL). Negative control conditions
contained only aprotinin-α2-PI1–8. Frozen sections were immunostained for
endothelial cells (CD31, in red), pericytes (NG2, in green), smooth-muscle
cells (α-SMA, in cyan) and nuclei (DAPI, in blue). Asterisks, enlarged aberrant
vascular structures. n = 3. (Scale bar: 20 μm.)
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∼30% of the α2-PI1–8-VEGF164 amount incorporated at day 0
(Fig. S3A). Furthermore, α2-PI1–8-VEGF164 extracted from gels
after 2 wk of in vivo incubation was capable of inducing endo-
thelial proliferation as efficiently as the nonimplanted factor (Fig.
S3B), indicating that gel incorporation effectively protects VEGF
bioactivity despite prolonged in vivo exposure. The extracted
factor showed a slightly reduced activity compared with fresh
recombinant VEGF (∼80% relative efficacy) as a consequence
of the prolonged manipulations necessary for the gel-extraction
procedure.
Dose-Dependent Angiogenesis by Fibrin-Bound α2-PI1–8-VEGF164. Since
decreasing α2-PI1–8-VEGF164 from 100 μg/mL to 25 μg/mL caused
a shift from completely aberrant to mostly normal angiogenesis,
we investigated the effects of lower α2-PI1–8-VEGF164 concen-
trations. Nine days after intramuscular injection, 5 μg/mL, 1 μg/mL,
and 0.1 μg/mL α2-PI1–8-VEGF164 all induced exclusively nor-
mal and mature capillaries, associated with nerve/glia antigen
2 (NG2)-positive and α-smooth muscle actin (α-SMA)-negative
pericytes (Fig. S4).
Sustained VEGF stimulation for at least 4 wk is necessary for
newly induced vessels to stabilize and become VEGF-independent
(7, 9, 10). Four weeks after intramuscular implantation of gels
carrying four different α2-PI1–8-VEGF164 concentrations (0.01
μg/mL, 0.1 μg/mL, 5 μg/mL, and 100 μg/mL), small amounts of
nondegraded gel were still detectable (Fig. S5), and robust an-
giogenesis was present in all conditions (Fig. 2 A and D). Similarly
to the 9-d results, 100 μg/mL α2-PI1–8-VEGF164 generated aber-
rant angioma-like structures mixed with more regular capillaries,
which were, however, completely devoid of mural cells whereas
both 0.1 μg/mL and 5 μg/mL induced exclusively normal net-
works of mature capillaries. Remarkably, the further 10-fold
lower VEGF concentration of 0.01 μg/mL also induced efficient
capillary growth, suggesting that normal angiogenesis can be
effectively generated by a very wide range of α2-PI1–8-VEGF164
doses. All vessels induced by α2-PI1–8-VEGF164 concentrations up
to 5 μg/mL displayed the morphology of normal skeletal-muscle
capillaries as they were covered by NG2+/SMA− pericytes, but
no SMA+ smooth muscle (22) and had homogeneous diameter
distributions in a narrow range within 10 μm (90th percentile,
0.01 μg/mL = 4.62 μm; 0.1 μg/mL = 4.53 μm; 5 μg/mL = 8.47 μm),
similar to normal capillaries in control tissues (90th percentile,
4.48 μm). In contrast, aberrant structures induced by 100 μg/mL
displayed very heterogeneous and enlarged sizes (90th percen-
tile, 16.05 μm) and were covered by a thick smooth-muscle coat
(Fig. 2 A and B). Interestingly, concentrations ≤0.1 μg/mL in-
duced vessels with the same average diameter as control tissue
whereas the capillaries induced by 5 μg/mL were significantly
larger (Fig. 2C), although homogeneous in size and smaller than
10 μm and normal in morphology. In contrast to vessel diame-
ters, the amount of angiogenesis, quantified as vessel length
density (VLD), did not depend on the α2-PI1–8-VEGF164 dose as
all concentrations between 0.01 μg/mL and 5 μg/mL similarly
increased VLD by 50–60% compared with controls (Fig. 2D).
Sustained vascular leakage is a side effect of VEGF delivery
that can lead to harmful tissue edema (23). Therefore, plasma
leakage was quantified 4 wk after implantation of gels containing
5 μg/mL α2-PI1–8-VEGF164: i.e., the highest concentration in-
ducing morphologically normal angiogenesis at the latest time
when gel-bound factor was still present (Fig. S5). Consistent with
previous results (7), newly induced normal vessels were not leaky
after 4 wk of VEGF delivery, with similar levels of Evans blue
extravasation as the background measured in control tissues
implanted with empty gels containing no VEGF (controls, 6.49 ±
1.54 ng Evans blue/mg tissue vs. VEGF, 5 μg/mL, 6.98 ± 1.83 ng
Evans blue/mg tissue; P = n.s.), suggesting they had acquired
normal functionality. Moreover, no macroscopic edema was
observed in the implanted limbs at any time up to 3 mo.
Long-Term Stability and Perfusion of Vessels Induced by Optimized
α2-PI1–8-VEGF164 Delivery.We assessed whether α2-PI1–8-VEGF164–
induced vessels had stabilized and achieved complete indepen-
dence from exogenous VEGF 3 mo after intramuscular gel injec-
tion. Angiogenesis was still present in all conditions, displaying
similar morphologies as after 4 wk (Fig. 3A) although no trace of
the injected gels could be found anymore (Fig. S5). All α2-PI1–8-
VEGF164 concentrations causing normal angiogenesis (0.01–
5 μg/mL) induced about a 70% increase in VLD, which was
also significantly more than the amount still present after delivery
of 100 μg/mL that induced aberrant angiogenesis (Fig. 3B). A
comparison between VLD after 3 mo and 4 wk showed that the
normal vessels generated by concentrations between 0.01 μg/mL
and 5 μg/mL were completely stable and even further increased
whereas greater than 60% of the aberrant vasculature induced
by 100 μg/mL regressed (Fig. 3C). Further, i.v. injection of
a fluorescein-labeled tomato lectin (FITC-lectin) showed that
essentially all endothelial structures induced by the different
α2-PI1–8-VEGF164 concentrations were reached by blood flow
and thereby functionally connected to the systemic circulation
both after 4 wk (Fig. S6) and 3 mo (Fig. S7), as demonstrated
by colocalization of CD31 immunostaining and FITC-lectin.
Therefore, optimized delivery of fibrin-bound α2-PI1–8-VEGF164
induced the growth of morphologically normal and mature
capillary networks that were both stable and functional.
Functional Improvement in Ischemia. Lastly, we tested the efficacy
of optimized delivery of fibrin-bound α2-PI1–8-VEGF164 to cause
functional improvement in two different rodent models of clin-
ically relevant ischemic diseases: i.e., hind-limb ischemia and
ischemic wound healing.
Based on the results described in Figs. 2 and 3 for normal
skeletal muscle, two α2-PI1–8-VEGF concentrations in a 10-fold
range (0.5 μg/mL and 5 μg/mL) were delivered through the opti-
mized gel composition in a murine model of hind-limb ischemia.
Fig. 2. Dose-dependent angiogenesis 4 wk after
optimized delivery of fibrin-bound α2-PI1–8-VEGF164.
Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8
and 0 μg/mL (negative control), 0.01 μg/mL, 0.1 μg/mL,
5 μg/mL, or 100 μg/mL α2-PI1–8-VEGF164 were injected
into gastrocnemius muscles of SCID mice. Tissues were
analyzed 4 wk later. (A) Frozen sections were immu-
nostained to detect endothelial cells (CD31, in red),
pericytes (NG2, in green), and smooth-muscle cells
(α-SMA, in cyan). n = 3. (Scale bar: 20 μm.) Asterisks,
enlarged aberrant vascular structures; arrowhead,
regular capillaries devoid of mural cells. (B and C )
Quantification of vessel diameters (n > 500 per group), shown as their distribution in 1-μm intervals (B) and mean ± SEM (C). (D) The amount of angiogenesis
was quantified as vessel length density (VLD): i.e., the total vessel length in the area of each measured field (n = 5–10 fields per group); ***P < 0.001, **P <
0.01 vs. negative control (NC).
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An empty gel of the same composition was used as a negative
control. Histological analysis (Fig. 4A) and VLD quantification
(Fig. 4C) showed that, after 4 wk, 0.5 μg/mL α2-PI1–8-VEGF164
promoted the growth of an abundant network of morphologically
normal and mature capillaries, associated with NG2+/SMA− per-
icytes, compared with negative control. However, contrary to the
results in normal muscle, 5 μg/mL α2-PI1–8-VEGF led to a lower
increase in VLD (Fig. 4C) and actually caused the growth of
aberrant angioma-like structures, devoid of pericytes, and en-
compassed by smooth-muscle cells (asterisk in Fig. 4A). Blood
flow was recorded by laser Doppler imaging both in the ischemic
and nonoperated contralateral leg preoperatively, immediately
after surgery and 7 d and 28 d later. To account for variables,
including ambient light and temperature, calculated perfusion
was expressed as a ratio of that in the ischemic to normal limb, as
previously described (24). Blood flow in ischemic muscles was
unaffected by 5 μg/mL α2-PI1–8-VEGF164 compared with control
(Fig. 4 B and D) but was significantly improved by 0.5 μg/mL
α2-PI1–8-VEGF164 after 4 wk compared with both control and
5 μg/mL VEGF (Fig. 4 B and D). Consistent with the improve-
ment in blood flow, after 4 wk, the 0.5 μg/mL α2-PI1–8-VEGF164
condition also significantly increased the number of histologi-
cally visible collateral arteries in the cranial part of the adductor
thigh muscles compared with both other treatments (Fig. 4E).
To determine the general applicability of this approach, we
further investigated whether the optimized delivery of fibrin-
bound α2-PI1–8-VEGF164 could promote functional improve-
ment in a distinct ischemic wound-healing model. Based on the
results described in Fig. 4, showing that the threshold between
normal and aberrant angiogenesis in ischemic tissue lies between
0.5 μg/mL and 5 μg/mL α2-PI1–8-VEGF164, a concentration of
2 μg/mL was used in the optimized fibrin-matrix composition as
the therapeutic condition, with an empty gel of the same com-
position as negative control. Histological analysis (Fig. S8 A and B)
and VLD quantification (Fig. S8 C and E) showed that, after 7 d,
treatment with α2-PI1–8-VEGF164 significantly increased dermis
vascularization both in nonischemic and ischemic wounds.
Microvessels were associated with NG2+ pericytes in all groups
(Fig. S8 A and B). Furthermore, α-SMA+ mural cells were found
associated with both microvessels and small-caliber arterioles
and venules (arrowheads in Fig. S8 A and B) because, contrary to
muscle tissue, in the skin, a proportion of capillary pericytes also
express α-SMA (25). The α2-PI1–8-VEGF164–treated tissues dis-
played a greater density of regularly shaped larger vessels (>15 μm)
with the features of arterioles (covered by a regular smooth-
muscle layer and homogeneous in size), consistently with the
previously described effect of VEGF to cause arteriolization of
preexisting vessels (26). Laser Doppler imaging showed that the
increased vessel density in the α2-PI1–8-VEGF164–treated wounds
correlated with significantly improved tissue perfusion both in
the nonischemic and ischemic sites by 7 d (Fig. S8 D, F, and G)
(P < 0.05).
To evaluate the functional effects of increased angiogenesis
and perfusion in the treated tissues, wound healing was analyzed.
Under nonischemic conditions (Fig. S9A), the control-treated
tissues showed signs of very mild inflammation with hyper/par-
akeratosis, without clearly identifiable dermis beneath the epi-
dermis and with bleeding areas. The underlying muscle layer was
fully infiltrated by inflammatory cells, and several muscle fibers
displayed signs of partial necrosis, evidenced by infiltration of
mononuclear inflammatory cells inside the myofibers. α2-PI1–8-
VEGF164 treatment slightly reduced epidermal hyperplasia,
above which a layer of keratinized tissue with several apoptotic
bodies was visible, whereas the stratus corneum was partially
present, indicating that the α2-PI1–8-VEGF164–treated tissue had
reached a more advanced stage of regeneration of the physiolog-
ical skin structure. Further, α2-PI1–8-VEGF164 treatment reduced
the inflammatory infiltrate in the underlying muscle layer and
completely prevented myofiber damage. Under ischemic conditions
Fig. 3. Long-term stability of normal, but not aberrant, angiogenesis in-
duced by optimized delivery of fibrin-bound α2-PI1–8-VEGF164. Fibrin gels
containing 56 μg/mL aprotinin-α2-PI1–8 and 0 μg/mL (negative control),
0.01 μg/mL, 0.1 μg/mL, 5 μg/mL, and 100 μg/mL α2-PI1–8-VEGF164 were injected
into gastrocnemius muscles of SCID mice. Tissues were analyzed 3 mo later.
(A) Frozen sections were immunostained to detect endothelial cells (CD31, in
red), pericytes (NG2, in green), and smooth-muscle cells (α-SMA, in cyan).
n = 3. (Scale bar: 20 μm.) (B) The amount of angiogenesis was quantified
as vessel length density (mean VLD ± SEM; n = 5–10 fields per group);
***P < 0.001 or **P < 0.01 vs. negative control, δδP < 0.01, δP < 0.05 vs. the
100 μg/mL condition. (C) The stabilization rate of vessels induced in each
condition was calculated as the percentage ratio between VLD 3 mo and
4 wk after gel injection (% Resistant fraction), with a value of 100% or higher
indicating complete stabilization and a value lower than 100% indicating
vascular regression between the two time points.
Fig. 4. Functional improvement of hind-limb ischemia by α2-PI1–8-VEGF164.
Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8 and 0 μg/mL (negative con-
trol), 0.5 μg/mL, and 5 μg/mL α2-PI1–8-VEGF164 were injected into the lower
thigh muscles. Tissues were analyzed 4 wk later. (A) Frozen sections were
immunostained to detect endothelial cells (CD31, in red), pericytes (NG2, in
green), and smooth-muscle cells (α-SMA, in cyan). n = 3. (Scale bar: 20 μm.) (B)
Representative laser Doppler images of nonischemic and ischemic limbs (left
and right side of each image, respectively) 28 d after treatment with control
gels (control) or 0.5 μg/mL and 5 μg/mL α2-PI1–8-VEGF164. (C) The amount of
angiogenesis was quantified as vessel length density (mean VLD ± SEM;
n = 5–10 fields per group); ***P < 0.001 and **P < 0.01 vs. negative
control, δP < 0.05 vs. the 0.5 μg/mL condition. (D) Blood flow was mea-
sured by laser Doppler imaging before surgery (preop) to set the base-
line, immediately after (postop) and 7 and 28 d later. Results were
expressed as the ratio between measured flow in the ischemic and the
contralateral nonoperated hind limb. (E ) The number of collateral
arteries was determined histologically in the adductor muscles after 4 wk
(mean ± SEM per field; n = 5–10 fields per group); *P < 0.05 vs. negative
control, δP < 0.05 vs. the 0.5 μg/mL condition.
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(Fig. S9B), control tissues displayed moderate hyperplasia of the
epidermis, which was covered with a thick keratinized tissue full
of apoptotic bodies. Both the dermis and the underlying muscle
layer were prominently infiltrated with inflammatory cells, the
muscle fibers were completely disorganized, many were invaded
by monocytes, and several degenerative vacuoles were visible
within the muscle layer. However, in the α2-PI1–8-VEGF164–
treated wounds, both epidermal hyperplasia and the thickness
of the keratinized tissue with apoptotic bodies were reduced
compared with controls. Further, α2-PI1–8-VEGF164 treatment
reduced the inflammatory infiltrate in the muscle layer and pre-
vented myofiber damage, avoiding tissue necrosis. Therefore,
histological analysis showed that treatment with α2-PI1–8-VEGF164
significantly improved tissue regeneration and restoration of the
physiological structure. Consistently, the quantification of wound-
healing rate showed that α2-PI1–8-VEGF164 promoted a significant
acceleration of ischemic wound closure 7 d after gel implantation
(Fig. S9D). Nonischemic wounds were also smaller both 3 d and
7 d after α2-PI1–8-VEGF164 treatment although the differences were
not statistically significant (Fig. S9C).
Discussion
Here, we found that the combination of fibrin-bound α2-PI1–8-
VEGF164 with the fibrin-bound fibrinolysis inhibitor aprotinin-
α2-PI1–8 provides a highly tunable platform to precisely control the
VEGF dose delivered to tissues and efficiently induce stable and
functional angiogenesis. Incorporation of aprotinin-α2-PI1–8 at
an optimal concentration is a key requirement to efficiently in-
duce normal angiogenesis in vivo through its control of fibrino-
lysis and thus release of α2PI1–8VEGF164. Although differing
release rates of the same α2-PI1–8-VEGF164 concentration could
cause disparate effects, from none to aberrant angiogenesis,
optimal gel degradation rates enabled fibrin-bound α2-PI1–8-
VEGF164 to reliably induce exclusively normal, mature, stable,
and functionally perfused microvascular networks over a 500-
fold range of concentrations in normal muscle tissue. Remarkably,
newly induced vessels did not regress for at least 3 mo whereas
the implanted gels were almost completely consumed by 4 wk,
demonstrating that they achieved independence from exogenous
VEGF signaling for their survival and suggesting that they could
persist indefinitely. This finding is particularly relevant for the
therapeutic potential of this approach because one of the main
limitations of recombinant protein delivery for therapeutic an-
giogenesis has been the insufficient duration of factor release to
achieve persistent effects (20). On the other hand, aberrant an-
giogenesis induced by 100 μg/mL α2-PI1–8-VEGF164 failed to
recruit physiological pericyte coverage by 4 wk, when gel-bound
factor was still present, consistently with the described function
of VEGF as a negative regulator of pericyte function through
formation of nonfunctional VEGFR-2/PDGFR-β complexes and
consequent inhibition of PDGFR-β phosphorylation (27). When
exogenous α2-PI1–8-VEGF-A164 became exhausted, more than
60% of the vascular structures induced by this high dose dis-
appeared, indicating that they could not stabilize despite sustained
VEGF release for at least 4 wk.
Therefore, incorporation of 56 μg/mL aprotinin-α2-PI1–8 en-
sured an optimal gel degradation rate in vivo, which is the key
parameter controlling both the duration and the effective dose of
factor delivery. Under these optimized conditions, the angio-
genic outcome was solely controlled by α2-PI1–8-VEGF164 con-
centration, with aberrant vascular structures being induced by
levels ≥25 μg/mL and physiological functional capillary networks
resulting from a wide range of doses 0.01–5 μg/mL. The high
tunability of the fibrin-bound delivery platform allowed us to
span an extremely wide range of VEGF doses, including those
determining the transition between normal and aberrant angio-
genesis, which is a key feature for the design of preclinical dose-
escalation studies. It should be noted that we chose to deliver the
syngenic mouse recombinant factor mVEGF164 instead of the
clinically used human homolog hVEGF165 because the experi-
ments were performed in a mouse model and we recently found
that the dose-dependent effects of VEGF are species-specific (28).
The concentration of α2-PI1–8-VEGF164 did not affect the
amount of induced vasculature because already the lowest dose
caused the maximum increase in VLD, which was maintained
over a 500-fold range. However, the dose of α2-PI1–8-VEGF164
influenced the size of induced vessels, which remained un-
affected by concentrations up to 0.1 μg/mL but was significantly
increased by 5 μg/mL. These results are relevant for the thera-
peutic potential of α2-PI1–8-VEGF164 delivery. In fact, we and
others have previously shown that the size of newly induced
vessels is key to determine the efficacy of therapeutic angio-
genesis approaches (29, 30) as a similar increase in number
without increase in size provided no therapeutic benefit (29).
Based on these considerations, two different α2-PI1–8-VEGF164
concentrations in the upper range of normal angiogenesis,
0.5 μg/mL and 5 μg/mL, were chosen to investigate dose-dependent
functional improvement in a hind-limb ischemia model. Results
showed that 0.5 μg/mL was effective to induce functional im-
provement as it caused a twofold increase in the amount of
normal capillaries and significantly increased blood flow in is-
chemic tissue compared with controls. However, 5 μg/mL α2-PI1–8-
VEGF164, which induced only normal and stable angiogenesis
in nonischemic muscle, actually stimulated the growth of aber-
rant vascular structures that failed to improve blood flow and
collateral arteriogenesis in ischemic tissue. This disparate effect
of the same concentration of α2-PI1–8-VEGF164 may be attrib-
utable to the elevated levels of inflammatory cells and proteases
during ischemia, which accelerate gel degradation and thus the
effective rate of growth factor release. These results highlight the
need to determine the therapeutic window of fibrin-bound
α2-PI1–8-VEGF164 delivery specifically for each envisioned clin-
ical application as the unique biological variables associated with
different pathologies can influence the effective degradation rate,
factor release, and angiogenic outcome.
Considering the results obtained in the normal and ischemic
hind limb, a concentration of 2 μg/mL was chosen to test the
functional efficacy of fibrin-bound α2-PI1–8-VEGF164 in an is-
chemic wound-healing model. The treatment with α2-PI1–8-
VEGF164 stimulated an 80% increase in normal angiogenesis,
which significantly improved tissue perfusion both in non-
ischemic and ischemic tissues. The angiogenic stimulus induced
a significant improvement of the wound closure in ischemic
conditions and a positive trend toward improvement in non-
ischemic tissues. Interestingly, in control conditions, ischemia
significantly slowed wound healing compared with normal tissue
(55% vs. 38% still-open wound size by 7 d), and α2-PI1–8-
VEGF164 treatment restored healing in ischemia to the
nonischemic level (36% still-open wound size by 7 d). In non-
ischemic tissue, α2-PI1–8-VEGF164 treatment provided a further
benefit (28% still-open wound size by 7 d), but the magnitude of
the difference was insufficient to reach statistical significance.
These data suggest that, in the absence of ischemia, tissue repair
proceeds already at physiological speed and that increased blood
flow could improve it only marginally whereas, in ischemic con-
ditions, impaired perfusion is the critical factor limiting wound
healing, and α2-PI1–8-VEGF164 treatment may unfold its thera-
peutic effect. Consistently with this concept, it has been pre-
viously found that skin wounding in normal conditions leads to
a transient localized ischemia due to microvascular damage and
a six- to sevenfold up-regulation of endogenous VEGF expres-
sion, but this up-regulation is not further increased if wounding is
carried out under conditions of ischemia (31).
In ischemic tissue, maximum blood supply is limited, and the
opening of collateral arteries (arteriogenesis) is required to re-
store physiological flow levels to meet the metabolic demands of
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regenerating tissue. Microvascular angiogenesis by VEGF can
induce arteriogenesis by increasing blood flow and shear stress
(1) and generating upstream responses through retrograde con-
duction along vessel walls via intercellular gap junctions (2).
However, in chronic ischemia, spontaneous angiogenesis is in-
sufficient to restore physiological flow, and we have previously
found that VEGF doses higher than the maximal up-regulation
achieved by the endogenous response are necessary to signifi-
cantly increase both the amount and size of microvascular net-
works, induce collateral arteriogenesis, and achieve therapeutic
benefit (29). Our results suggest that such doses can be effec-
tively achieved in ischemic tissue by optimized delivery of fibrin-
bound α2-PI1–8-VEGF164. However, as the specific conditions
prevalent in different tissues and pathologic states dictate the
actual degradation rate and therefore the effective growth factor
release in vivo, it is impossible to define a general therapeutic
window. In this respect, the high tunability of the optimized
platform developed in this study, with normal and stable angio-
genesis being induced in healthy skeletal muscle over a 500-fold
range of α2-PI1–8-VEGF164 concentrations, provides a key en-
abling tool for specific dose-finding studies for each envisioned
clinical application, such as peripheral or coronary artery dis-
ease, or chronic wounds, so that dosage can be carefully de-
termined and adapted.
Methods
Detailed information is provided in SI Methods.
Recombinant α2PI1–8-VEGF164 Production and Purification. The transglutaminase
substrate sequence NQEQVSPL (α2-PI1–8) was fused to the N terminus of the
mouse VEGF-A164 cDNA by PCR. The fusion protein was expressed into
Escherichia coli strain BL21 (De3) pLys (Novagen) and isolated as described
previously (32) and in SI Methods.
Intramuscular Fibrin-Gel Implantation. Fifty microliters of fibrin hydrogel,
prepared as described in SI Methods, was aspirated with an insulin syringe
with integrated 30G needle (Becton Dickinson) and injected into the gas-
trocnemius muscle of 6- to 8-wk-old immunodeficient SCID CB.17 mice
(Charles River), previously anesthetized by 3% isofluorane inhalation.
Hind-Limb Ischemia. Hind-limb ischemia experiments were performed on
female CD1-mice (Charles River) by unilateral femoral artery ligation and
excision, as detailed in SI Methods. Blood flow was measured by a laser
Doppler imaging system (Moor Instruments), and results were presented as
a ratio of the flow in the ischemic to that in the contralateral normally
perfused hind limbs to account for variables, including ambient light and
temperatures, as previously described (24) and as detailed in SI Methods.
Ischemic Wound Healing. An ischemic wound-healing model was performed
on male Sprague–Dawley rats (Harlan-Winkelmann; n = 6 per group), based
on a modification of a previously described epigastric flap model (33) and as
detailed in SI Methods.
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SI Methods
Recombinant α2PI1–8-VEGF164 Production and Purification.The cDNA
for mouse VEGF-A164 was PCR-amplified using primers de-
signed to allow for fusion of the transglutaminase substrate se-
quence NQEQVSPL, comprising the 8 N-terminal residues of
α2-plasmin inhibitor (α2-PI1–8) onto the N terminus of the am-
plified cDNA before insertion into the expression vector pRSET
(Invitrogen). The fusion protein was expressed in Escherichia coli
strain BL21 (De3) pLys (Novagen). The recombinant α2-PI1–8-
VEGF-A164 was isolated from inclusion bodies, processed, and
refolded using a slightly modified version of a previously pub-
lished protocol (1). Briefly, the inclusion bodies were collected
from the bacterial lysate by centrifuging, washed with Triton X-
114 to remove membrane proteins and endotoxins, and extracted
with urea buffer overnight at 4 °C under magnetic stirring.
Further dimerization of α2-PI1–8-VEGF-A164 was done with
a redox system (0.5 mM oxidized glutathione, 5 mM reduced
glutathione) added into the protein solution after the 2 M urea
dialysis, and α2-PI1–8-VEGF-A164 was dimerized under stirring
for 48 h at 4 °C. Then, glutathione and urea were removed by
three sequential dialyses of 24 h against Tris buffers. Proteins
were then concentrated using a 10-kDa Amicon tube (Millipore,
Merck) and further filtered through a 0.22-μm filter. α2PI1–8-
VEGF164 monomers and dimers were separated using size ex-
clusion with a HiLoad 16/60 Superdex 75-pg column (GE
healthcare). Fractions corresponding to α2PI1–8-VEGF dimers
were pooled together, concentrated with Amicon tubes, and
filtered through a 0.22-μm filter. α2PI1–8-VEGF dimers were
verified to be >99% pure by SDS/PAGE and MALDI-TOF
analysis. Endotoxin level was verified to be under 0.05 EU/mg of
protein using the LAL assay (GenScript).
Fibrin-Gel Preparation. Fibrin matrices were prepared by mixing
human fibrinogen (plasminogen-, von Willebrand Factor-, and
fibronectin-depleted; Enzymes Research Laboratories), factor
XIIIa (CSL Behring), and thrombin (Sigma-Aldrich) combined at
different concentrations as described in Results with 2.5 mM
Ca2+ in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes)
(Lonza). Matrices containing aprotinin-α2-PI1–8 [produced as
described (2)] and α2-PI1–8-VEGF164 were obtained by adding the
engineered proteins to the cross-linking enzymes solution before
mixing with fibrinogen. Matrices were allowed to polymerize at
37 °C for 1 h before use or directly injected after mixing to allow
in situ polymerization, depending on the experimental design.
α2-PI1–8-VEGF-A164 Release Profile from Fibrin Hydrogels. Fibrin
matrices of 50 μL volume were generated with 10 mg/mL fi-
brinogen, 2 U/mL thrombin, 5 U/mL factor XIII, 5 mM calcium
chloride as previously described for this assay (3), and 10 μg/mL
VEGF-A164 (R&D Systems) or of α2-PI1–8-VEGF164. Fibrin gels
were polymerized at 37 °C for 1 h and transferred into 24-wells
containing 500 μl of washing buffer. The 100% release control
well contained only the growth factor in buffer. Every 24 h,
buffers were collected, stored at −20 °C and replaced with fresh
buffer. For the 100% release control well, 20 μl of buffer was
taken out every day and stored at −20 °C. After 7 d, the cu-
mulative release of growth factor was quantified by ELISA using
the 100% released control as reference (DuoSet; R&D Systems).
VEGF-R2 Phosphorylation Assay.Human umbilical vein endothelial
cells (HUVECs) (PromoCell) were seeded in 96-well plates
(3,000 cells per well) and starved 4 h with serum-free MCDB-131
medium (Invitrogen). Cells were then stimulated with 50 ng/mL
VEGF-A164 or α2-PI1–8-VEGF-A164 for 5 min. Phosphorylated
VEGF-R2 was quantified with a phospho-ELISA kit. Briefly,
ELISA plates were coated with a capture antibody for VEGF-R2
and then incubated with cell lysates. The phosphorylation state
was detected with an anti-phospho-tyrosine antibody and nor-
malized to a standard according to manufacturer instructions
(phospho-VEGF-R2/KDR, DuoSet IC; R&D Systems).
In Vitro Gel Polymerization. Fibrin matrices of 50 μL volume were
prepared onto a plastic minitray (Nunc Microwell Minitrays;
Sigma-Aldrich) and placed on ice to slow down gel polymeri-
zation. The fibrinogen solution was first deposited into the well
with a pipette tip, avoiding the formation of bubbles, and the
cross-linking enzyme solution was added. Solutions were mixed
three times with the pipette to guarantee homogenous mixing.
The start of polymerization was defined by the change of consis-
tency from liquid to stiff as detected by touch with the pipette tip.
Rheology. Fibrin-gel discs of 1-mm thickness were preformed into
press-to-seal silicone isolator slides (Invitrogen) coated with
parafilm at room temperature. Gels were allowed to polymerize
for 1 h at 37 °C, removed from the support, and placed in PBS
overnight at 4 °C to allow swelling. Gel stiffness was determined
by performing small-strain oscillatory shear rheometry using
a Bohlin CVO 120 high-resolution rheometer with plate–plate
geometry at room temperature (Instrumat SA). Gels were sand-
wiched between the two plates of the rheometer with compression
up to 80% of their original thickness to avoid slipping. Measure-
ments were then conducted in a constant strain (0.05) mode as a
function of frequency (from 0.1 Hz to 10 Hz) to obtain dynamical
spectra (n = 3 per condition).
Intramuscular Fibrin-Gel Implantation. To avoid an immunological
response to human fibrinogen and cross-linking enzymes, 6- to
8-wk-old immunodeficient CB.17 SCID mice (Charles River
Laboratories) were used. Animals were treated in accordance
with the Swiss Federal guidelines for animal welfare, after ap-
proval from the Veterinary Office of the Canton of Basel-Stadt
(Basel, Switzerland). A liquid volume of 50 μL was aspirated
rapidly with a 0.3-mL insulin syringe with integrated 30 G needle
(Becton Dickinson) and injected into the gastrocnemius muscle
of the mice previously anesthetized with 3% isofluorane in-
halation. After injection, in situ polymerization was allowed for
20 s before slowly extracting the needle.
In Vivo Multispectral Imaging. Fibrin gels were prepared as pre-
viously described, but fluorescent Alexa 647-conjugated fibrin-
ogen (Invitrogen) was included at a concentration of 0.5 ng/mL to
monitor the degradation of the different fibrin-gel compositions
in vivo by noninvasive multispectral imaging. The experiments
were performed at the Ludwig Boltzmann Institute after approval
by the local ethical committee. Animals were treated according to
the National Institutes of Health guidelines. Carprofen (2.5 mg/kg;
Pfizer) was administered to animals preoperatively and for the
following 3 d to ensure analgesia. A liquid volume of 50 μL was
injected into gastrocnemius muscles on both hindlimbs of BALB/c
nu/nu nude mice (n = 10 per group). The fluorescence of the fi-
brin matrix was noninvasively followed and quantified over a pe-
riod of 9 d using a multispectral imaging system (Maestro Imaging
System; CRI). Regions of interest were defined and analyzed. The
signal (given as counts per s) was normalized to the values ob-
tained on day 1 and expressed as a percentage.
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Histological Analyses. Mice were anesthetized with Ketamin (100
mg/kg) and Xylazin (10 mg/kg) i.p. and euthanized by vascular
perfusion of 1% paraformaldehyde (PFA) (Sigma-Aldrich) in
PBS (pH 7.4) for 3 min under 120 mm/Hg of pressure. Gas-
trocnemius muscles were harvested, postfixed in 0.5% PFA in
PBS (pH 7.4) for 2 h at room temperature, and cryoprotected in
30% (wt/vol) sucrose in PBS at 4 °C overnight. Muscles were
embedded in optimal cutting temperature (OCT) compound
(CellPath), frozen in freezing isopentane, and cryosectioned.
Tissue sections were stained with H&E to verify the intramuscular
localization of the gel. Vascular morphology was analyzed by im-
munofluorescence staining on 12-μm-thick frozen sections cut
along the longitudinal axis. The following primary antibodies and
dilutions were used: rat anti-mouse CD31 (clone MEC 13.3; BD
Bioscences) at 1:100; mouse anti-human α-SMA (clone 1A4;
Sigma-Aldrich) at 1:400; and rabbit anti-rat NG2 (Millipore,
Merck) at 1:200. Fluorescently labeled secondary antibodies
(Invitrogen) were used at 1:200. Fluorescence images were
taken with a 40× objective on a Carl Zeiss LSM710 3-laser
scanning confocal microscope (Carl Zeiss).
In some experiments, the amount of nondegraded gel was
assessed histologically by immunostaining with a primary anti-
body that specifically recognizes fibrin, but not fibrinogen (mouse
anti-human fibrin, clone E8; Beckman Coulter Immunotech) at
a dilution of 1:200. Tissue sections were obtained at 250-μm
intervals, in three muscles per group (n = 3). Images were taken
in each section where gel was detectable with a 10× objective on
an Olympus BX61 fluorescence microscope (Olympus) and merged
using the multiple image alignment (MIA) function of the CellP
imaging analysis software (Olympus) to reconstruct the total
area of the tissue section in which the nondegraded gel was present.
The total surface area occupied by nondegraded gel was quantified
(in mm2) using ImageJ software (http://rsb.info.nih.gov/ij/) as the
sum of all sections in each analyzed muscle.
In some experiments, physiological perfusion of induced vessels
was assessed by intravascular staining with a fluorescently labeled
Lycopersicon esculentum (tomato) lectin (Vector Laboratories)
that binds the luminal surface of blood vessels, as previously
described (4). Briefly, mice were anesthetized, and lectin was
injected i.v. (50 μL of a 2 mg/mL lectin solution per mouse) and
allowed to circulate for 4 min before vascular perfusion of 1%
PFA in PBS (pH 7.4) for 3 min under 120 mm/Hg of pressure.
Vessel Measurements. Vessel diameters and vessel length density
(VLD) were measured in muscle cryosections after immunos-
taining for CD31, NG2, and SMA as previously described (4, 5).
Briefly, vessel diameters were measured by overlaying captured
microscopic images with a square grid. Squares were selected
randomly, and the diameter of each vessel, if present, in the
defined square was measured (in μm). Around 500 total diameter
measurements were obtained from three independent muscles for
each group (n = 3). VLD was measured in 5–10 fields per muscle
from three muscles per group (n = 3) by tracing the total length
of vessels in each field and dividing it by the area of the field (mm
of vessel length/mm2 of surface area). All analyses were per-
formed using the Cell P imaging software (Olympus).
Subcutaneous Fibrin-Gel Implantation. All animal procedures were
approved by the Cantonal Veterinary Office of Canton Zurich
(Zurich, Switzerland). Female Crl:CD1 Foxn1nu nude mice were
used at 4–5 wk of age. Gel implantation and excision was per-
formed as described (6). Briefly, animals were anesthetized by
inhalation of 2% isofluorane. The dorsal skin was disinfected
with 70% ethanol. Two incisions, ∼1.5 cm long, were made along
the left and right sides of the dorsum. Four gels of 20 μL volume
were implanted in each mouse in a random order, a 10–0 Dafilon
suture (Braun) was placed through each fibrin-gel pellet to fasten
the gel to the s.c. area just beneath the skin, and wounds were
closed with 7–0 Prolene sutures (Ethicon). Animals were eutha-
nized 14 d later by carbon dioxide asphyxiation. Gels were excised
together with the surrounding skin, and samples were stored at
−80 °C for further analysis.
α2-PI1–8-VEGF-A164 Protein Extraction and Quantification. The con-
centration of α2-PI1–8-VEGF164 in the gels after in vivo im-
plantation was measured from explanted and frozen fibrin gels as
described (6). They were washed in PBS for 8 h at 4 °C, changing
the PBS every hour. Afterward, 50 mU of plasmin (Sigma-Aldrich)
in 50 μL of deionized water were added to each gel and incubated
at 37 °C on a shaker at 1,000 rpm. After 8 h, the plasmin solution
was renewed and incubation at 37 °C on a shaker continued until
all gels were completely dissolved (∼48 h). The amount of VEGF
in the resulting samples was measured using an ELISA kit (R&D
Systems). One hundred microliters of each sample was used in
triplicate, and the assay was performed according to the manu-
facturer’s instructions.
Endothelial Cell Proliferation Assay. VEGF biological activity was
assessed in a HUVEC proliferation assay as described (6). Cells
were cultured in 96-well plates (5,000 cells per well) in EGM-2
fully supplemented growth medium (Lonza) in 5% CO2 at 37 °C.
Before the assay, cells were starved for 6 h with EBM-2 medium
(Lonza) supplemented with 1% FCS. Stimulation was started by
supplementing the EBM-2 medium with 50 ng of the α2-PI1–8-
VEGF164 liberated from the gels or 50 ng of recombinant mouse
VEGF164 (Peprotech) as a positive control. Cell numbers were
determined 72 h later by adding 10 μl of cell proliferation re-
agent (WST-1; Roche) to each well. After 4 h of incubation,
absorbance of the samples was measured at 650 nm using a mi-
croplate reader (Biotek).
Plasma-Leakage Measurements. Evans Blue assays were performed
as described previously (5). Four weeks after gel implantation,
Evans Blue dye (30 mg/kg of mouse body weight in 100 μL of
PBS) (Sigma) was injected into the femoral vein. After 4 h, mice
were perfused with 1% paraformaldehyde in 0.05 M citric acid
(pH 3.5), and the gastrocnemius muscles were harvested and
weighed. Evans Blue was extracted from tissue with formamide
at 55 °C overnight and measured with a spectrophotometer at
610 nm. Plasma leakage was expressed as nanograms of extra-
vasated dye per milligram of tissue wet weight (n = 4 per group).
Hind-Limb IschemiaModel and Analysis.Experiments were performed
at the Ludwig Boltzmann Institute (Vienna), after approval by the
local ethical committee. The hind-limb ischemia was performed
on female CD1 mice (n = 11 per group), weighing 28–36 g (Charles
River). Mice were anesthetized with isoflurane (2.5 vol %), and
femoral artery ligation and excision were performed unilaterally
according to a randomization protocol. Under a surgical micro-
scope, the femoral artery was ligated proximally (inguinal ligament)
and distally (bifurcation into saphenous and popliteal artery) and
excised. The wound was closed using nonabsorbable sutures in
a single-knot technique. The contralateral normally perfused hind
limb of each animal served as an internal control. Gels containing
either 0 μg/mL, 0.5 μg/mL, or 5 μg/mL α2-PI1–8-VEGF164 were
injected into the distal part of the quadriceps (50 μL), adductor
(30 μL), and biceps femoris (30 μL) thigh muscles of mice
according to a randomization protocol. As analgesic treatment,
animals received 0.1 mg/kg buprenorphin preoperatively and
1.5 mg/kg meloxicam for the first 3 d after surgery. Hind-limb
blood flow was measured by a laser Doppler imaging system
(LDI) (Moor Instruments), preoperatively as baseline, post-
operatively to assess effective induction of ischemia, and on days 7
and 28. Data analysis was performed with the Moor LDI image
processing software (Version 5.3; Moor Instruments). The scan
mode was set at 10 ms per pixel, and a resolution of 256 × 256
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pixels was chosen. Blood flow was calculated as a ratio of that in
the ischemic to that in the contralateral normally perfused hind
limbs to account for variables, including ambient light and tem-
peratures, as previously described (7). On day 28, mice were an-
esthetized with ketamine (67 mg/kg) and xylazine (13 mg/kg) i.p
before intravascular systemic perfusion with 1% PFA in PBS
(pH 7.4) for 3 min under 120 mm/Hg of pressure. The adduc-
tor, biceps, and quadriceps femoris muscles were harvested,
postfixed in 0.5% PFA in PBS (pH 7.4) for 2 h at room tem-
perature, cryoprotected in 30% (wt/vol) sucrose in PBS at 4 °C
overnight, embedded in OCT compound (CellPath), frozen in
freezing isopentane, and cryosectioned.
Tissue sections were analyzed to assess the intramuscular lo-
calization of the implanted gel, vessel morphology, and length
density as described in Histological Analyses and Vessel Mea-
surements. After serial sectioning of the entire adductor muscles,
the number of collateral arteries was quantified on a single
section from each sample, so as to avoid double counting, taken
from the proximal part of the muscle in an area remote from the
area of injection of the gel and where no angiogenesis was detect-
able. Collateral vessels >20 μm in diameter were quantified by
costaining for CD31 and α-SMA as previously described (8) on
three to six random fields per muscle, acquired with a 20× objective
on an Olympus BX61 fluorescence microscope (Olympus). Re-
sults were expressed as collaterals per field of view (n = 3 muscles
per group).
Ischemic Wound-Healing Model and Analysis. Experiments were
performed at the Ludwig Boltzmann Institute (Vienna), after
approval by the local ethical committee. An ischemic wound-
healing model was performed on male Sprague–Dawley rats (n =
6 per group), weighing 300–350 g (Harlan-Winkelmann), based
on a modified epigastric flap model as previously described (9).
Briefly, the rats were anesthetized with ketamine (110 mg/kg)
and xylazine (12 mg/kg) i.p. A square skin flap of 8 cm by 8 cm
was elevated from cranial to caudal and remained connected to
blood circulation only at the caudal base. Half of the flap was
rendered ischemic by ligating the left or right inferior neuro-
vascular bundle, and the flap was sutured back. The flap was
divided into three vertical zones of equal size, the outer zone on
the ligation side reflecting ischemic tissue and the opposite one
reflecting vital areas. A 1.5-cm-diameter circular wound was
created within the elevated flap in the middle of each outer
zone, thus resulting in an ischemic wound on one side and an
internal control wound on the opposite side. A volume of 100 μL
of optimized-composition gel with 56 μg/mL aprotinin-α2-PI1–8,
either empty or containing 2 μg/mL α2-PI1–8-VEGF164, was ap-
plied at the wound sites according to a randomization protocol,
allowing solidification in situ. Wounds were covered with
a transparent foil dressing (Opsite; Smith and Nephew) and fixed
with a second dressing (Fixomull-stretch), changing them on day
1 and 3. As an analgesic treatment, rats received 1.25 mg/kg
butorphanol and 0.15 mg/kg meloxicam s.c. on the day of surgery
and 3 d later.
Superficial tissue perfusion was measured by a laser Doppler
imaging system (Moor Instruments), preoperatively as baseline,
postoperatively to assess effective induction of ischemia, and on
days 3 and 7. Preoperative baseline values were set at 100%, and
subsequent scans were normalized to these values and expressed
as a percentage of baseline. The ischemic and nonischemic
vertical zones were scanned and evaluated separately. The scan
modewas set at 10ms per pixel, and a resolution of 256× 256 pixels
was chosen. Analyses were made by a software evaluation tool
provided with the LDI Moor system (Moor Instruments). Per-
fusion values were recorded as colored pixels, giving the color-
coordinated 2D image of the flap perfusion.
Wound closure was evaluated by planimetric analysis. Excision
wounds were traced on a transparent acrylic sheet postsurgery
and at days 3 and 7. The sheets were photographed with adjacent
standard ruler and analyzed by a planimetric software (Lucia G1,
Version 4.8; Laboratory Imaging). The results were expressed as
a percentage of the total postoperative wound surface area. On
day 7, the animals were euthanized by an intracardiac injection of
150 mg/kg Pentobarbital, and the entire wound areas were ex-
cised. Tissues were fixed in 4% (wt/vol) neutral-buffered formalin
for 24 h, dehydrated in ascending concentrations of alcohol,
embedded in paraffin, and 4-μm-thick sections were cut on a ro-
tary microtome. The samples were warmed to 60 °C for 30 min,
deparaffinized in xylene, and rehydrated in graded alcohols. A
blocking treatment (1% H2O2 in distilled water) to deactivate
endogenous peroxidase was performed for 10 min. NG2 stain-
ing was performed with 1:100 rabbit anti-rat NG2 antibody
(Millipore, Merck) overnight at 4 °C, without epitope retrieval.
Samples were rinsed with Tris-buffered saline (TBS) for 5 min
and incubated with anti-rabbit antibody labeled with biotin
(Dako) for 1 h at room temperature, followed by staining with
a biotin substrate kit (VECTASTAIN Elite ABC kit; Vector
Labs).
Samples for von Willebrand Factor (vWF) antibody were
pretreated with proteinase K (Dako) for 8 min whereas samples
for SMA staining underwent heat-induced epitope retrieval for
around 20 min at 95 °C in Tris-EDTA buffer (Zytomed). All
slides were moved to immunostaining chambers (Coverplate
System; Thermo Shandon) and washed with TBS for 5 min. The
tissue sections were incubated with 1:100 vWF antibody (poly-
clonal rabbit anti-human, A0082; Dako) and with 1:5,000 SMA
antibody (monoclonal mouse anti-human, A2547; Sigma-Aldrich)
for 1 h at room temperature. After rinsing with TBS, anti-mouse
or anti-rabbit HRP-labeled micropolymers (Dako) were applied
to the slides for 30 min at room temperature, followed by staining
with a peroxidase substrate kit (ImmPACT NovaRED; Vector
Labs). The slides were then counterstained with hematoxylin, de-
hydrated, and mounted with Entellan mounting medium (Merck).
Statistics.Data are presented as mean ± SEM. The significance of
differences was evaluated using analysis of variance (ANOVA)
followed by the Bonferroni test (for multiple comparisons) or
using a Mann–Whitney test (for single comparisons), and P <
0.05 was considered statistically significant.
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Fig. S1. Characterization of the fusion protein α2-PI1–8-VEGF164. (A) Percent cumulative release of α2-PI1–8-VEGF164 and native VEGF164 from fibrin gels. The
quantity of native and variant VEGF164 was measured on buffer collected and replaced daily for 7 d by ELISA. Values are reported as mean ± SEM (n = 3). (B)
Phosphorylation assay. Serum-starved HUVECs were incubated with 50 ng/mL native VEGF164 or α2-PI1-8-VEGF164, and the amount of phosphorylated VEGF-
Receptor 2 (VEGF-R2) was quantified by ELISA (ng/mL). Values are reported as mean ± SEM (n = 3); ***P < 0.001.
Fig. S2. In vivo gel degradation. (A) Gel compositions of different stiffness were injected into the gastrocnemius muscles of SCID mice. Immunofluorescence
staining of serial tissue sections with a fibrin-specific antibody showed no significant differences in the amount of remaining gel 4 d after injection. Results are
shown as mean gel area (mm2) ± SEM (n = 3). (B) Different gel compositions spanning the whole range of stiffnesses were prepared with fluorescently labeled
fibrinogen and injected into gastrocnemius muscles. The degradation was monitored in vivo daily for a period of 9 d by noninvasive imaging of fibrin
fluorescence. Results are shown as percentage of the initial fluorescent signal remaining over time (mean ± SEM; n = 9).
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Fig. S3. The biological activity of α2-PI1–8-VEGF164 is preserved after 2 wk of in vivo implantation. Fibrin gels of 20 μL volume containing 100 μg/mL α2-PI1–8-
VEGF164 and 56 μg/mL aprotinin-α2-PI1–8 were preformed in vitro and frozen at −80 °C either immediately (day 0) or 2 wk after s.c. implantation into nude mice
(day 14). (A) After digestion with plasmin for ∼56 h at 37 °C, the amount of extracted α2-PI1–8-VEGF164 was measured by ELISA. Results are shown as mean
concentration in the extraction supernatant (ng/mL) ± SEM (n = 4). (B) The biological activity of the extracted α2-PI1–8-VEGF164 was determined in a HUVEC
proliferation assay. Recombinant fresh VEGF164 was used as positive control. Results are shown as the percentage residual activity in cell proliferation compared
with fresh recombinant VEGF, set at 100% (mean ± SEM; n = 4).
Fig. S4. A wide range of α2-PI1–8-VEGF164 doses induces robust and normal angiogenesis. Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8 and 0 μg/mL
(negative control), 5 μg/mL, 1 μg/mL, or 0.1 μg/mL α2-PI1–8-VEGF164 were injected into the gastrocnemius muscles of SCID mice. Tissues were analyzed 9 d later,
and frozen sections were immunostained to detect endothelial cells (CD31, in red), pericytes (NG2, in green), smooth-muscle cells (α-SMA, in cyan), and nuclei
(DAPI, in blue). n = 3. (Scale bar: 20 μm.)
Fig. S5. In vivo persistence of optimized fibrin gels. Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8 and 0.1 μg/mL α2-PI1–8-VEGF164 were injected into the
gastrocnemius muscles of SCID mice. Tissues were analyzed 9 d, 1 mo, or 3 mo later, and frozen sections were immunostained to detect fibrin (anti-fibrin
antibody, in green) and nuclei (DAPI, in blue). Abundant gel is visible 9 d after injection whereas, after 4 wk, small residues are still present and none is
detectable after 3 mo. (Scale bar: 20 μm.)
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Fig. S6. Vessels induced by α2-PI1–8-VEGF164 are functionally perfused after 4 wk. Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8 and 0.01 μg/mL, 0.1 μg/mL,
5 μg/mL, and 100 μg/mL α2-PI1–8-VEGF164 were injected into gastrocnemius muscles of SCID mice. FITC-lectin was injected i.v. into mice 4 wk later, just before
euthanizing. Endothelial structures (EC) were stained with an antibody against CD31 (red) whereas FITC-lectin is shown in green. Perfused vessels were
identified as staining positive for both CD31 and FITC-lectin. n = 3. (Scale bar: 20 μm.)
Fig. S7. Vessels induced by α2-PI1–8-VEGF164 are functionally perfused after 3 mo. Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8 and 0.01 μg/mL, 0.1 μg/mL,
5 μg/mL, and 100 μg/mL α2-PI1–8-VEGF164 were injected into gastrocnemius muscles of SCID mice. FITC-lectin was injected i.v. into mice 3 mo later, just before
euthanizing. Endothelial structures (EC) were stained with an antibody against CD31 (red) whereas FITC-lectin is shown in green. Perfused vessels were
identified as staining positive for both CD31 and FITC-lectin. n = 3. (Scale bar: 20 μm.)
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Fig. S8. α2-PI1–8-VEGF164 significantly improves angiogenesis and tissue perfusion in an ischemic wound-healing model. Fibrin gels containing 56 μg/mL
aprotinin-α2-PI1–8 alone (CTRL) or with 2 μg/mL α2-PI1–8-VEGF164 were placed on circular wounds in either nonischemic or ischemic dorsal skin flaps in Sprague–
Dawley rats. (A and B) Tissues were harvested 7 d later, and paraffin sections were immunostained to detect endothelial cells [von Willebrand Factor (vWF)],
pericytes (NG2), and smooth-muscle cells (SMA). n = 6. (Scale bar: 20 μm.) Arrowheads, α-SMA–positive microvessels and small-caliber arterioles and venules.
(C and E) The amount of angiogenesis was quantified as vessel length density (VLD), and results are shown as mean ± SEM (n = 5–10 fields per group); ***P <
0.001, **P < 0.002. (D and F) Tissue blood perfusion was quantified by laser Doppler imaging after flap elevation with (F) or without (D) arterial ligation [post-
operative (postop)] and 3 d and 7 d after gel implantation. Results show the amount of perfusion as a percentage of the nonischemic baseline set at 100% (mean ±
SEM; n = 6); *P < 0.05. (G) Representative laser Doppler images of nonischemic and ischemic wounds (Left and Right side of each image, respectively) 7
d after treatment with control gels (CTRL) or α2-PI1–8-VEGF164.
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Fig. S9. α2-PI1–8-VEGF164 significantly improves wound regeneration in an ischemic wound-healing model. Fibrin gels containing 56 μg/mL aprotinin-α2-PI1–8
alone (CTRL) or with 2 μg/mL α2-PI1–8-VEGF164 were placed on circular wounds in either nonischemic or ischemic dorsal skin flaps in Sprague–Dawley rats. (A and B)
Tissues were harvested 7 d later, and paraffin sections were stained with H&E. Images were acquired both in the superficial layer (DERMIS) and in the un-
derlying muscle layer (MUSCLE). n = 6. (Scale bar: 20 μm.) Arrowheads, epidermal hyperplasia; thick arrow, bleeding area; asterisks, monocyte infiltration of
muscle fibers; thin arrows, keratinized tissue with apoptotic bodies. (C and D) Wound healing was measured by planimetric analysis 3 and 7 d after gel im-
plantation, and results show the size of still-open wounds as a percentage of the initial size at day 0, set at 100% (mean ± SEM; n = 6); *P < 0.05.
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